Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 18/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.66 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631266 | 0.91 | OPRK1 (0.66) | OPRK1CYP2D6OPRD1UTS2ROPRM1 | |
| SCHEMBL5630756 | 0.87 | OPRK1 (0.63) | OPRK1CYP2D6OPRD1OPRM1 | |
| SCHEMBL5629262 | 0.87 | OPRK1 (1.00) | OPRK1CYP2D6OPRD1OPRM1CYP3A4 | |
| SCHEMBL8459482 | 0.87 | OPRK1 (1.00) | OPRK1CYP2D6OPRD1OPRM1CYP3A4 | |
| SCHEMBL5629650 | 0.84 | OPRK1 (0.75) | OPRK1CYP2D6OPRD1UTS2ROPRM1 | |
| SCHEMBL7176760 | 0.84 | OPRK1 (0.75) | OPRK1CYP2D6OPRD1UTS2ROPRM1 | |
| SCHEMBL5630376 | 0.83 | OPRK1 (0.75) | OPRK1CYP2D6OPRD1OPRM1CYP3A4 | |
| SCHEMBL8457976 | 0.82 | OPRK1 (0.52) | OPRK1CYP2D6OPRD1UTS2ROPRM1 | |
| SCHEMBL6487620 | 0.81 | OPRK1 (0.74) | OPRK1CYP2D6OPRD1UTS2ROPRM1 | |
| SCHEMBL10434997 | 0.80 | OPRK1 (0.86) | OPRK1CYP2D6OPRD1OPRM1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960612-B2 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION (US) | 2005-11-01 | — | — | US | claimed |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2004-11-04 | — | — | US | claimed |
| US-20030236248-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | KRUSE LAWRENCE I (US) | 2003-12-25 | — | — | US | claimed |
| US-20020042399-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-04-11 | — | — | US | claimed |
| JP-2001510154-A | — | — | 2001-07-31 | — | — | JP | claimed |
| EP-0998281-A1 | KAPPA AGONIST COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND METHOD OF PREVENTION AND TREATMENT OF PRURITUS THEREWITH | Adolor Corporation (US) | 2000-05-10 | — | — | EP | claimed |
| US-6028063-A | ADMINISTERING COMPOUND WITH OPIOID ACTIVITY | ADOLOR CORPORATION (US) | 2000-02-22 | — | — | US | claimed |
| WO-1999003468-A1 | KAPPA AGONIST COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND METHOD OF PREVENTION AND TREATMENT OF PRURITUS THEREWITH | ADOLOR CORPORATION (US) | 1999-01-28 | — | — | WO | claimed |
| US-7294647-B2 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION (US) | 2007-11-13 | — | — | US | disclosed |
| US-6960612-B2 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2005-01-27 | — | — | US | disclosed |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-6750216-B2 | HETEROCYCLIC AMINES SUCH AS 2-(2-(N-METHYLSULFAMOYL)-4-METHOXY -PHENYL)-N-METHYL-N-((1S)-1-PHENYL-2-((1-PYRROLIDINYL)ETHYL)) ACETAMIDE, ADMINISTERED AS ANALGESICS | ADOLOR CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-20030236248-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | KRUSE LAWRENCE I (US) | 2003-12-25 | — | — | US | disclosed |
| US-6057323-A | PIPERAZINE DERIVATIVES | ADOLOR CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-6054445-A | KAPPA OPIOID AGONIST ACTIVITY; ANALGESICS AND ANTI-PRURITIC AGENTS | ADOLOR CORPORATION (US) | 2000-04-25 | — | — | US | disclosed |
| US-5945443-A | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION (US) | 1999-08-31 | — | — | US | disclosed |
| US-5763445-A | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION (US) | 1998-06-09 | — | — | US | disclosed |
| US-5744458-A | ANALGESICS | ADOLOR CORPORATION (US) | 1998-04-28 | — | — | US | disclosed |
| US-5688955-A | ANALGESICS | ADOLOR CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236248-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 946/4885OPRD1 2/4885 |
| US-20020042399-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 843/4885OPRD1 2/4885 |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 886/4885OPRD1 2/4885 |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 541/4885OPRD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.